Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias. Twenty-eight patients received the construct intravenously at four dose levels (12, 18, 28 and 40 mg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Borthakur, Gautam, Rosenblum, Michael G., Talpaz, Moshe, Daver, Naval, Ravandi, Farhad, Faderl, Stefan, Freireich, Emil J., Kadia, Tapan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Cortes, Jorge E.
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2013
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3561428/
https://ncbi.nlm.nih.gov/pubmed/22875630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.071092
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars